Paclitaxel

Catalog No.S1150 Synonyms: NSC 125973

Paclitaxel Chemical Structure

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 22 Publications

6 Customer Reviews

  • (F) Kaplan-Meier curves are shown for all groups described: no hydrogel, a hydrogel loaded with paclitaxel, or a hydrogel loaded with doxorubicin. The number of mice per group (n) and median survival (ms) are listed. The experiment was performed at least three times.

    Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Paclitaxel purchased from Selleck.

    Effect of tivantinib on the mitotic index was compared with the antimitotic drugs paclitaxel and vinblastine after overnight treatment of the HLE cell line with two different concentrations of each drug.

    Clin Cancer Res, 2017, 23(15):4364-4375. Paclitaxel purchased from Selleck.

  • Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

    Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

    Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

  • Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

    Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Targets
Microtubule (human endothelial cells) [1]
0.1 pM
In vitro

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwMECwNlg4KM7:TR?= NHfSTHZUSU6JRWK=
LC-2-ad NVfyfYJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[1RmlEPTB;MD6wNFA{OTdizszN MULTRW5ITVJ?
RL95-2 MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7jT4IzUUN3ME2wMlAxODZ4ODFOwG0> NFz2NmxUSU6JRWK=
MZ1-PC Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7FOIxKSzVyPUCuNFAxPzJ7IN88US=> NEfGTZpUSU6JRWK=
TE-8 M3zVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwMECxNVch|ryP Mm[4V2FPT0WU
SW954 M4Ozb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDDTWM2OD1yLkCwNVE6KM7:TR?= NYL6SHFmW0GQR1XS
TE-11 NILrNlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e2SWlEPTB;MD6wNFEzOyEQvF2= NGnoe|hUSU6JRWK=
PSN1 NUTT[|F3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\pXmlEPTB;MD6wNFE{KM7:TR?= NWTpW25pW0GQR1XS
MOLT-4 NEDGPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwMECxOFkh|ryP NH\LTJNUSU6JRWK=
697 NEnwfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwMECxOUDPxE1? MXHTRW5ITVJ?
ETK-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DOe2lEPTB;MD6wNFE2OiEQvF2= NYXqdo83W0GQR1XS
TE-10 NYLHbYNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXwUnBOUUN3ME2wMlAxOTV2IN88US=> NXnMdlI1W0GQR1XS
HUTU-80 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrwcFVKSzVyPUCuNFAyPjhizszN NUnvXVJKW0GQR1XS
NTERA-S-cl-D1 NFThbVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETXUo1KSzVyPUCuNFAzODlizszN NVTDPIV5W0GQR1XS
MFH-ino NIDrXGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXRNIVKSzVyPUCuNFAzPjhizszN M2GwVHNCVkeHUh?=
IA-LM MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnnRYpHUUN3ME2wMlAxOjhizszN NH\tc45USU6JRWK=
MC116 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHX[|ZKSzVyPUCuNFAzQDlizszN NWSzT3NCW0GQR1XS
RKO NFyyVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PGOmlEPTB;MD6wNFI6QCEQvF2= MVfTRW5ITVJ?
MRK-nu-1 NWLHeHBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PhTGlEPTB;MD6wNFI6QSEQvF2= MnuwV2FPT0WU
VA-ES-BJ M4qxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLSTWM2OD1yLkCwN{DPxE1? NFTXXVhUSU6JRWK=
KALS-1 Ml\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;5eYV7UUN3ME2wMlAxOzB6IN88US=> NX:wPVhkW0GQR1XS
BB30-HNC NWnD[5kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHjTWM2OD1yLkCwN|E1KM7:TR?= MYTTRW5ITVJ?
ACN NF31XWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPNTY9rUUN3ME2wMlAxOzF4IN88US=> Mne3V2FPT0WU
TE-9 NF3aNGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT1WnJKSzVyPUCuNFA{OjZizszN NYSy[4g3W0GQR1XS
SIG-M5 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[zVWlEPTB;MD6wNFMzPyEQvF2= MU\TRW5ITVJ?
no-10 M4m4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\mbppKSzVyPUCuNFA{PjJizszN NI\NeW5USU6JRWK=
EW-1 M2q5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoD1TWM2OD1yLkCwN|cyKM7:TR?= NWnZPWxoW0GQR1XS
SK-LMS-1 M17NUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrjWYZKSzVyPUCuNFA1ODFizszN NWfY[ZFXW0GQR1XS
GT3TKB Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fp[2lEPTB;MD6wNFQ{PCEQvF2= M1\5T3NCVkeHUh?=
ES4 NGrnTHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vZcGlEPTB;MD6wNFQ1QSEQvF2= NYi5ZYxMW0GQR1XS
IMR-5 Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTBwMEC0OUDPxE1? M4npcXNCVkeHUh?=
NCI-H1648 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3GclJKSzVyPUCuNFA1PjlizszN NV7rNJhEW0GQR1XS
MV-4-11 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;4b2lEPTB;MD6wNFQ4PSEQvF2= MXHTRW5ITVJ?
SK-UT-1 NYTjbItiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPHUopKSzVyPUCuNFA1QCEQvF2= M3;hbHNCVkeHUh?=
NB13 NVLJWHl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnm2TWM2OD1yLkCwOFkyKM7:TR?= MVLTRW5ITVJ?
DJM-1 M{DINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvPOoxKSzVyPUCuNFA2OyEQvF2= MkiwV2FPT0WU
ES8 MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwMEC1N|gh|ryP MlHTV2FPT0WU
TE-6 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jNZWlEPTB;MD6wNFU4KM7:TR?= NYfYcGVLW0GQR1XS
KS-1 M{DkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPUNlRKSzVyPUCuNFA2QDJizszN NVXVWHNSW0GQR1XS
TE-1 NInGZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMEC2NFYh|ryP NU\vVJFmW0GQR1XS
ATN-1 NX:zXYdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7SV|hmUUN3ME2wMlAxPjB7IN88US=> NFLwVWVUSU6JRWK=
A4-Fuk MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXwUFF5UUN3ME2wMlAxPjFzIN88US=> NH7BVZdUSU6JRWK=
ALL-PO NVm3WpNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\DV2lEPTB;MD6wNFY{KM7:TR?= MmrUV2FPT0WU
BE-13 MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\v[m9sUUN3ME2wMlAxPjN4IN88US=> NHzZeYRUSU6JRWK=
KM12 M1XZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjvTWM2OD1yLkCwOlM4KM7:TR?= NWq3O3ZCW0GQR1XS
NOS-1 NID1OFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[yTWM2OD1yLkCwOlUh|ryP NFPrc5BUSU6JRWK=
SW962 MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlH3TWM2OD1yLkCwOlYzKM7:TR?= NIrXUWZUSU6JRWK=
OCUB-M NXf1fWt7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmX0TWM2OD1yLkCwOlYzKM7:TR?= M2TMOnNCVkeHUh?=
NCI-H510A NHj2doRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWG3fGd3UUN3ME2wMlAxPjZ3IN88US=> M1LlSXNCVkeHUh?=
EW-16 Ml\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TjZWlEPTB;MD6wNFY6PCEQvF2= M3[zUXNCVkeHUh?=
KGN MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMEC3NVIh|ryP NVfPcWhwW0GQR1XS
LS-411N M2nmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHITWM2OD1yLkCwO|E4KM7:TR?= MVrTRW5ITVJ?
Becker Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFG5V|hKSzVyPUCuNFA4OiEQvF2= NIDkeGhUSU6JRWK=
HC-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMEC3NlEh|ryP MVTTRW5ITVJ?
CESS M2jWTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwMEC3N|ch|ryP MVrTRW5ITVJ?
KURAMOCHI NFjDUWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHGZoZIUUN3ME2wMlAxPzR6IN88US=> NWru[GZLW0GQR1XS
TGBC24TKB Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;OS2lEPTB;MD6wNFc2OiEQvF2= MYrTRW5ITVJ?
SW982 MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;RTWM2OD1yLkCwO|Y3KM7:TR?= NVPoc3o3W0GQR1XS
HCE-4 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LDZ2lEPTB;MD6wNFc3PyEQvF2= MWrTRW5ITVJ?
LOUCY M3S0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjoTWM2OD1yLkCwO|c2KM7:TR?= M2W3Z3NCVkeHUh?=
8-MG-BA M1ezbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwMEC3PVYh|ryP M3XoS3NCVkeHUh?=
HT-144 NXnSRmpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfqPZdKSzVyPUCuNFA5KM7:TR?= NVjlZ2dtW0GQR1XS
LXF-289 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwMEC4NVgh|ryP MXHTRW5ITVJ?
RS4-11 Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwMEC4N|Yh|ryP NH:zN21USU6JRWK=
DEL MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fMTWlEPTB;MD6wNFg1PSEQvF2= NGTv[G1USU6JRWK=
OCI-AML2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjJRZhKSzVyPUCuNFA5PTJizszN MVrTRW5ITVJ?
CCRF-CEM M33MbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrhR3pKSzVyPUCuNFA5PzFizszN MWPTRW5ITVJ?
A388 NHjiXFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwMEC4O|Qh|ryP MmnUV2FPT0WU
KNS-42 M{f2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwMEC4PVEh|ryP NWTCTmY5W0GQR1XS
OVCAR-4 NGTGb4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Pyc2lEPTB;MD6wNFkxPCEQvF2= MWrTRW5ITVJ?
NCI-H1355 MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrMTWM2OD1yLkCwPVE1KM7:TR?= MYXTRW5ITVJ?
BL-70 NWTLc|lMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PVVGlEPTB;MD6wNFk{KM7:TR?= M1XaV3NCVkeHUh?=
BL-41 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;mVGlEPTB;MD6wNFk{PCEQvF2= M1rHVnNCVkeHUh?=
A101D NFXPTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17qZmlEPTB;MD6wNFk3KM7:TR?= NGfQNXBUSU6JRWK=
HL-60 NV:4TYluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DqcmlEPTB;MD6wNFk3PiEQvF2= NVLVU3NHW0GQR1XS
COR-L279 NGTCWHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rmR2lEPTB;MD6wNFk6QSEQvF2= MUXTRW5ITVJ?
NCI-SNU-16 M{\VXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwMEGwNFgh|ryP MoD4V2FPT0WU
Calu-6 NWrMVG5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMEGwNVIh|ryP MUPTRW5ITVJ?
SR M4nSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPE[|BKSzVyPUCuNFExOjZizszN NV;BS2VqW0GQR1XS
QIMR-WIL MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjhZYVOUUN3ME2wMlAyODN|IN88US=> M{e4S3NCVkeHUh?=
LB647-SCLC NWTu[phPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPXbXFKSzVyPUCuNFExPTFizszN NHLYXJZUSU6JRWK=
RPMI-8226 M{[zTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwMEGxNFIh|ryP MUTTRW5ITVJ?
SK-PN-DW NUO5d|lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3vcHlsUUN3ME2wMlAyOTF{IN88US=> MYjTRW5ITVJ?
SF268 MlizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMEGxOVEh|ryP NEnJUodUSU6JRWK=
HD-MY-Z M2PwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[0ZmNVUUN3ME2wMlAyOTZ|IN88US=> NFXQRlZUSU6JRWK=
DOHH-2 MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVf1fmtQUUN3ME2wMlAyOjB|IN88US=> MWrTRW5ITVJ?
SCC-3 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD4WGw{UUN3ME2wMlAyOjB2IN88US=> NGi4PGtUSU6JRWK=
ST486 M1HB[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHTeHBLUUN3ME2wMlAyOjB2IN88US=> MWLTRW5ITVJ?
NALM-6 MnTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMEGyNVQh|ryP MlzFV2FPT0WU
NCI-H1436 NVLycJk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDSTWM2OD1yLkCxNlMyKM7:TR?= MoPPV2FPT0WU
KE-37 NHHXUJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwMEGyN|Qh|ryP MVnTRW5ITVJ?
RPMI-8402 NFvFe|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHKTWM2OD1yLkCxNlU3KM7:TR?= MVXTRW5ITVJ?
RXF393 MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\G[ZF{UUN3ME2wMlAyOjV5IN88US=> NWXiNJlSW0GQR1XS
KARPAS-45 MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTrPGdKSzVyPUCuNFEzPyEQvF2= NWrRRZZuW0GQR1XS
HOP-62 NVrWenhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33NemlEPTB;MD6wNVI4PiEQvF2= M{K0bHNCVkeHUh?=
ES1 MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXOeHRGUUN3ME2wMlAyOjh6IN88US=> M3zMWnNCVkeHUh?=
L-363 NXGxNWFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMEGzOVEh|ryP NUPib2NSW0GQR1XS
GI-1 NGDoVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnLSmsxUUN3ME2wMlAyOzd|IN88US=> M2Hyb3NCVkeHUh?=
CTV-1 NInnUYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnOcmxGUUN3ME2wMlAyPDd6IN88US=> MVzTRW5ITVJ?
TE-5 NUX0OGFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMEG0PVYh|ryP M{iweHNCVkeHUh?=
SNU-C2B MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwMEG0PVYh|ryP Mn;2V2FPT0WU
K-562 MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DmdGlEPTB;MD6wNVUyPiEQvF2= NEfDNGZUSU6JRWK=
SNB75 NWDuUnRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnUdGxNUUN3ME2wMlAyPTRizszN MUTTRW5ITVJ?
MOLT-13 M3nyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMEG2N|ch|ryP NGHvSVdUSU6JRWK=
LS-123 MlrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwMEG2OlQh|ryP MWrTRW5ITVJ?
NCI-SNU-5 NGnRZmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnKxTWM2OD1yLkCxO|AyKM7:TR?= MoG4V2FPT0WU
Daudi NFnRenFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TPfmlEPTB;MD6wNVcxQCEQvF2= MnHYV2FPT0WU
A253 NGXTR5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHq3Z5VKSzVyPUCuNFE4OzhizszN M{fnVnNCVkeHUh?=
TGBC1TKB M1TRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnZVWVKSzVyPUCuNFE4PTJizszN NXrUPYJjW0GQR1XS
SJSA-1 NGn5XINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWm0N3pVUUN3ME2wMlAyPzZ5IN88US=> M3n3UnNCVkeHUh?=
NCCIT MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DQZ2lEPTB;MD6wNVc3QSEQvF2= M{mxTXNCVkeHUh?=
NCI-H69 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;HUpZvUUN3ME2wMlAyPzd6IN88US=> NHfNTplUSU6JRWK=
SH-4 NETkRldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q5[WlEPTB;MD6wNVg6PSEQvF2= MX\TRW5ITVJ?
HCC1187 MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLOSmJKSzVyPUCuNFE6OjRizszN MoXFV2FPT0WU
HCC1599 NV;wWndvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGf6O3NKSzVyPUCuNFIxOiEQvF2= MlXTV2FPT0WU
ONS-76 NHrxcpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUS1W5Z4UUN3ME2wMlAzODN4IN88US=> NG\q[|JUSU6JRWK=
KU812 NXX3NmxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMEKwN|kh|ryP MkDtV2FPT0WU
ML-2 NVLTWHBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTBwMEKwOFch|ryP MWXTRW5ITVJ?
HCE-T Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fiTmlEPTB;MD6wNlA6OiEQvF2= MoT4V2FPT0WU
NCI-H446 MnnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmL0TWM2OD1yLkCyNVEzKM7:TR?= NXjZ[ppJW0GQR1XS
RPMI-6666 M37EW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMEKxOFkh|ryP MlTMV2FPT0WU
MOLT-16 MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4D3T2lEPTB;MD6wNlE2OyEQvF2= NHfvOplUSU6JRWK=
JiyoyeP-2003 NYHZPItYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPlWItKSzVyPUCuNFIyPzZizszN MkDGV2FPT0WU
MHH-PREB-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Xoe2lEPTB;MD6wNlE6OSEQvF2= M4G1PHNCVkeHUh?=
MC-CAR NVG2W2k2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLlTWM2OD1yLkCyN|I3KM7:TR?= MlG0V2FPT0WU
BC-3 NVntcZgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nWO2lEPTB;MD6wNlM1PCEQvF2= NUDVfmcyW0GQR1XS
KINGS-1 M2DnWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTHNIhmUUN3ME2wMlAzOzV3IN88US=> M3XsVHNCVkeHUh?=
PF-382 NHrw[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDyNGJ2UUN3ME2wMlAzOzd6IN88US=> MmnKV2FPT0WU
J-RT3-T3-5 NVvweGhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHUNWxKSzVyPUCuNFI{QDNizszN MWjTRW5ITVJ?
SF539 M4\uW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHiwWmFKSzVyPUCuNFI1ODFizszN NEO3RohUSU6JRWK=
LB831-BLC NVv6S4VkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;6fVhmUUN3ME2wMlAzPDh3IN88US=> MVjTRW5ITVJ?
DMS-114 M1jUNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwMEK1NFIh|ryP MYTTRW5ITVJ?
LB1047-RCC NWnlXlV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rYe2lEPTB;MD6wNlUyKM7:TR?= NIPSTY5USU6JRWK=
LB771-HNC NXnWfJlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHKTZJKSzVyPUCuNFI2OzRizszN MnzCV2FPT0WU
BB65-RCC M4rl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnSU5hOUUN3ME2wMlAzPTN2IN88US=> M3TvWXNCVkeHUh?=
BV-173 MlHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1G1O2lEPTB;MD6wNlU2PCEQvF2= NEXVOIxUSU6JRWK=
ARH-77 M3TFPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTjTWM2OD1yLkCyOlAyKM7:TR?= MVfTRW5ITVJ?
IST-MEL1 NH3MdWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne5TWM2OD1yLkCyOlI{KM7:TR?= MVfTRW5ITVJ?
NB1 MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnr3TWM2OD1yLkCyOlg4KM7:TR?= M{HW[nNCVkeHUh?=
EoL-1-cell NVO2OW5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHHfo9KSzVyPUCuNFI3QDhizszN NWXzb|dXW0GQR1XS
KY821 MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnYXFA4UUN3ME2wMlAzPjl5IN88US=> M{TNOXNCVkeHUh?=
CMK NVjtfXVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHITWM2OD1yLkCyO|M1KM7:TR?= NUfEVIJ6W0GQR1XS
NCI-H2126 NWjQRpRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHFdXVKSzVyPUCuNFI4PjhizszN M4nCVHNCVkeHUh?=
NCI-H526 MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zBWWlEPTB;MD6wNlg6OSEQvF2= MWfTRW5ITVJ?
COLO-684 MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEiyNW5KSzVyPUCuNFI6ODhizszN M4nTeXNCVkeHUh?=
NCI-H747 NV6wNYs5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\XNm54UUN3ME2wMlAzQTN|IN88US=> NEXvWnpUSU6JRWK=
JAR MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnNXnlHUUN3ME2wMlAzQTR4IN88US=> Ml;XV2FPT0WU
MEG-01 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwMEK5O|gh|ryP MkH4V2FPT0WU
MONO-MAC-6 NVHONlFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\mWoRKSzVyPUCuNFMxOjNizszN MXjTRW5ITVJ?
IST-SL1 NXzFW|VUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLw[YdKSzVyPUCuNFMxPDJizszN MmS5V2FPT0WU
CPC-N Ml:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoiwTWM2OD1yLkCzNFc6KM7:TR?= MVzTRW5ITVJ?
NCI-H1963 NVfON2YyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;0TWM2OD1yLkCzNVMyKM7:TR?= NHPkPFVUSU6JRWK=
K052 MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHjTXpYUUN3ME2wMlA{OjR5IN88US=> MnXQV2FPT0WU
KM-H2 NXv6cWZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMEOzNFch|ryP MYLTRW5ITVJ?
TE-12 M1HBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLH[otKSzVyPUCuNFM{ODlizszN M1\KWnNCVkeHUh?=
TK10 MmK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnCOmdvUUN3ME2wMlA{OzV4IN88US=> MonGV2FPT0WU
NMC-G1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPMTWM2OD1yLkCzOFUzKM7:TR?= NF3ZOHlUSU6JRWK=
no-11 MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMEO0O|gh|ryP MWXTRW5ITVJ?
NCI-H524 M3yxTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXVTWM2OD1yLkCzOVI6KM7:TR?= M2q3cHNCVkeHUh?=
MHH-CALL-2 M1ztNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXl[mtKSzVyPUCuNFM2PjJizszN MX\TRW5ITVJ?
GB-1 MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEX4UWFKSzVyPUCuNFM3KM7:TR?= MXHTRW5ITVJ?
OPM-2 NIjDbpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnacpZ1UUN3ME2wMlA{Pjd|IN88US=> NFfo[IxUSU6JRWK=
RH-1 M4f2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTobVhKSzVyPUCuNFM5OTlizszN M{HOUXNCVkeHUh?=
NCI-H64 M3XISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TWN2lEPTB;MD6wN|g2PyEQvF2= M3;GT3NCVkeHUh?=
EVSA-T NVTUPWR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7BTWM2OD1yLkCzPVI{KM7:TR?= NInpfmdUSU6JRWK=
KARPAS-299 M3zxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;ETWM2OD1yLkCzPVgh|ryP NGXMO|BUSU6JRWK=
MZ7-mel M{m5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMESwOEDPxE1? NFjyVFFUSU6JRWK=
LB373-MEL-D MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnMZVZlUUN3ME2wMlA1OTB3IN88US=> MmHsV2FPT0WU
HEL M3HFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXofmpmUUN3ME2wMlA1OTRizszN MVzTRW5ITVJ?
SW872 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmf4TWM2OD1yLkC0NlEh|ryP M1P3fnNCVkeHUh?=
DU-4475 NEmxN21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPve|lKSzVyPUCuNFQzPDRizszN MoHqV2FPT0WU
IST-SL2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrUOHVbUUN3ME2wMlA1Ojd3IN88US=> NH3qN5RUSU6JRWK=
NCI-H82 Ml;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv4TWM2OD1yLkC0N|A4KM7:TR?= NHrKOXFUSU6JRWK=
LC4-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPGcWZXUUN3ME2wMlA1OzVzIN88US=> NEC1Z5lUSU6JRWK=
HDLM-2 M1vxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDDNmVKSzVyPUCuNFQ{QTJizszN MkL5V2FPT0WU
MMAC-SF MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrzTWM2OD1yLkC0OVM1KM7:TR?= NF2yNnBUSU6JRWK=
L-540 NWPRV4RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMES2N|kh|ryP MV\TRW5ITVJ?
MZ2-MEL NVXJSop2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHXPXBQUUN3ME2wMlA1PzR{IN88US=> MnXxV2FPT0WU
LU-134-A M4j2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXnZ5RTUUN3ME2wMlA1Pzd|IN88US=> NXG1dHBCW0GQR1XS
UACC-257 M4HWZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTTTWM2OD1yLkC0PFQ6KM7:TR?= M3\NdXNCVkeHUh?=
NCI-H1581 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrmXG5KSzVyPUCuNFQ6PTNizszN MXXTRW5ITVJ?
NB17 NFzTdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvOdoJWUUN3ME2wMlA1QTd7IN88US=> NWjsR4l3W0GQR1XS
SBC-1 M363TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPWTWM2OD1yLkC1NFQzKM7:TR?= NXXJc|hHW0GQR1XS
TALL-1 MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMEWwOFUh|ryP MkT4V2FPT0WU
NCI-H1304 NHzpSm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3S1UWlEPTB;MD6wOVIxQCEQvF2= MY\TRW5ITVJ?
NEC8 MnnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTBwMEWyPFYh|ryP MVnTRW5ITVJ?
CAL-148 NIrRPHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjaTWM2OD1yLkC1OFM6KM7:TR?= MVvTRW5ITVJ?
CGTH-W-1 NXi5[4IxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwMEW0OFkh|ryP NY\0fHNNW0GQR1XS
NCI-H889 NXe4ZoFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PzXWlEPTB;MD6wOVU6OiEQvF2= NHnlfGNUSU6JRWK=
GR-ST M4flOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrHPG1KSzVyPUCuNFU3OjFizszN NWjkNVNZW0GQR1XS
KARPAS-422 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXG1b2tKUUN3ME2wMlA2PjVizszN NXz0c2I{W0GQR1XS
RPMI-8866 MkTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3KZZZWUUN3ME2wMlA2PzF{IN88US=> MnfhV2FPT0WU
SCLC-21H MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMEW4PFQh|ryP NIPaNZFUSU6JRWK=
COR-L88 M3KwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXK0PGF[UUN3ME2wMlA2QTJ5IN88US=> MW\TRW5ITVJ?
LU-139 NHXFS25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwMEW5PFYh|ryP MWLTRW5ITVJ?
SF126 M4jGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXPbIVKSzVyPUCuNFYyOzNizszN MXTTRW5ITVJ?
NCI-H1882 M1flWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TsZ2lEPTB;MD6wOlQzPCEQvF2= NX7sdZZ5W0GQR1XS
EW-24 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXicppCUUN3ME2wMlA3PDh|IN88US=> M{nnXHNCVkeHUh?=
CP67-MEL NIPiVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwME[4NUDPxE1? NYLOfmllW0GQR1XS
DG-75 NEm5[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonlTWM2OD1yLkC2PFk6KM7:TR?= NGjLZW5USU6JRWK=
LOXIMVI MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[yTWM2OD1yLkC3NFI5KM7:TR?= NF\XcmxUSU6JRWK=
HH NV3IUFJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MneyTWM2OD1yLkC3NVU4KM7:TR?= M1fmOHNCVkeHUh?=
K5 NHfPbVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTncnFKSzVyPUCuNFczOjZizszN M{DCbXNCVkeHUh?=
EC-GI-10 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLEb2I5UUN3ME2wMlA4OjV5IN88US=> NFnRVldUSU6JRWK=
SK-N-DZ MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PpVmlEPTB;MD6wO|MxPyEQvF2= M{DYTnNCVkeHUh?=
A3-KAW NIXrcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MliyTWM2OD1yLkC3N|UyKM7:TR?= M37XeXNCVkeHUh?=
MLMA NHH4dJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2frSmlEPTB;MD6wO|Q3PSEQvF2= NXvQTI9nW0GQR1XS
LB996-RCC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDxbpFKSzVyPUCuNFc4ODdizszN MUPTRW5ITVJ?
OS-RC-2 MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwMEe3OFgh|ryP NEG3WnBUSU6JRWK=
CTB-1 M{Hjbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTJTVlCUUN3ME2wMlA4QDFizszN M3PZTHNCVkeHUh?=
IST-MES1 NEnLc2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\xbGlEPTB;MD6wO|kyOiEQvF2= NGfzNI1USU6JRWK=
LS-1034 MljGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi2R3VtUUN3ME2wMlA5ODN3IN88US=> M17iWXNCVkeHUh?=
HT MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzJVW1xUUN3ME2wMlA5ODh4IN88US=> MofhV2FPT0WU
NCI-H2141 NFfDN|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3njcmlEPTB;MD6wPFEh|ryP MV;TRW5ITVJ?
LB2518-MEL MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HTdGlEPTB;MD6wPFE1OSEQvF2= M4LPdXNCVkeHUh?=
GI-ME-N NFr2Z49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLG[JZvUUN3ME2wMlA5PDV{IN88US=> M3vHfXNCVkeHUh?=
TGW MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkS1TWM2OD1yLkC4OlA4KM7:TR?= M{nTbnNCVkeHUh?=
SK-NEP-1 MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwMEi2OFEh|ryP Ml\SV2FPT0WU
NOMO-1 NFnOcIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPRUFlKSzVyPUCuNFkzPzVizszN M1;1enNCVkeHUh?=
ES6 NV7OXlBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3jTWM2OD1yLkC5OVg6KM7:TR?= NWPNVGRtW0GQR1XS
NCI-H209 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnPRZVCUUN3ME2wMlA6Pzh4IN88US=> Mm[2V2FPT0WU
GAK NYnYSoxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LTPWlEPTB;MD6xNFE3KM7:TR?= NHXafHlUSU6JRWK=
BC-1 M4HKO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LsRWlEPTB;MD6xNFM3OSEQvF2= NX\kWngyW0GQR1XS
KLE NVLVZol[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjqc|RKSzVyPUCuNVA1PDNizszN M4LtV3NCVkeHUh?=
EW-3 NECwU5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnJbJpxUUN3ME2wMlExQThizszN NV;EZVBCW0GQR1XS
NKM-1 NFLa[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwMUGxJO69VQ>? NYGyOFV1W0GQR1XS
D-336MG Mnf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwMUGyOFQh|ryP MYrTRW5ITVJ?
NB69 M3vpRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfBTWM2OD1yLkGxN|AyKM7:TR?= NFrMdJBUSU6JRWK=
D-263MG NID6S|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljaTWM2OD1yLkGxO|EzKM7:TR?= M4W2ZXNCVkeHUh?=
KP-N-YS MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMUKyPVEh|ryP MkfaV2FPT0WU
NCI-H1155 MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17rTWlEPTB;MD6xNlU2QCEQvF2= MUTTRW5ITVJ?
BOKU MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzJXXVsUUN3ME2wMlEzPTd7IN88US=> NEfGVnNUSU6JRWK=
LAMA-84 NYTQUFVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkf3TWM2OD1yLkGyPVkh|ryP MUPTRW5ITVJ?
Raji M3vpO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXQ[5RKSzVyPUCuNVMyOTdizszN M3LRNnNCVkeHUh?=
LU-65 NWLHN29TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXMTWM2OD1yLkGzN|A4KM7:TR?= Mn76V2FPT0WU
NCI-H187 MoXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMUO5NlQh|ryP NXfNcGcxW0GQR1XS
GCIY M{PNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\5R2lZUUN3ME2wMlE1QTBzIN88US=> NVHifldKW0GQR1XS
NCI-H2107 NVXsfpRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMUWwPEDPxE1? NUWwXIR3W0GQR1XS
NCI-H1522 NVzZfFFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PPfWlEPTB;MD6xOVI3PiEQvF2= M32xNXNCVkeHUh?=
NB6 MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXGwfGRiUUN3ME2wMlE2PjJ|IN88US=> M2jsUnNCVkeHUh?=
EM-2 M4TlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULtcYFVUUN3ME2wMlE2PzB4IN88US=> MUPTRW5ITVJ?
HCC2218 M4X5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMUW5PEDPxE1? M2H4cnNCVkeHUh?=
NCI-H748 MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfEV4JKSzVyPUCuNVY{PzZizszN MWDTRW5ITVJ?
MS-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33ufmlEPTB;MD6xOlU{PyEQvF2= MVzTRW5ITVJ?
NB5 NUPOR|NWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoH4TWM2OD1yLkG2OVk4KM7:TR?= NIiwUYdUSU6JRWK=
OMC-1 Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nObGlEPTB;MD6xOlY5QCEQvF2= NEn5TnJUSU6JRWK=
NCI-H345 NGjGOWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnobHhKSzVyPUCuNVY6OjhizszN NYe4doJvW0GQR1XS
L-428 NXOydFlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwMU[5OFUh|ryP M1znXnNCVkeHUh?=
SCH M1vLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETLfo5KSzVyPUCuNVg3QDVizszN MlTaV2FPT0WU
NCI-H1417 NH\t[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGO5WldKSzVyPUCuNVkzOjdizszN MmKyV2FPT0WU
COLO-320-HSR MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NET3NW5KSzVyPUCuNVk2OzJizszN MljaV2FPT0WU
BT-474 Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjQOYZHUUN3ME2wMlIxQDl{IN88US=> Mn;sV2FPT0WU
GDM-1 NHv4[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[2dGlEPTB;MD6yNVk4OSEQvF2= NUf2V4JyW0GQR1XS
NCI-H2196 MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPMXplUUUN3ME2wMlIzOjN3IN88US=> NFXFNIVUSU6JRWK=
KP-N-RT-BM-1 NFL4UI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwMkKzOFkh|ryP MoTVV2FPT0WU
KNS-81-FD M33ROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPPZ5d{UUN3ME2wMlIzQTV6IN88US=> M1T0RXNCVkeHUh?=
COLO-668 Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI[xWJJKSzVyPUCuNlM3PzVizszN MUjTRW5ITVJ?
C2BBe1 NHfiS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LaZWlEPTB;MD6yOlc1PyEQvF2= M2D2OHNCVkeHUh?=
Ramos-2G6-4C10 NU[0NHBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXzXotlUUN3ME2wMlI3QTV2IN88US=> M4XyVXNCVkeHUh?=
CAS-1 MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfVTWM2OD1yLkK3NFk3KM7:TR?= NHvZRYxUSU6JRWK=
GOTO NHWzOotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4SwVmlEPTB;MD6yO|g6PCEQvF2= NWTYcVNYW0GQR1XS
LP-1 M2fLS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnpTWM2OD1yLkK4NFU4KM7:TR?= MX3TRW5ITVJ?
NCI-SNU-1 Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwMkm0NlIh|ryP M3Pre3NCVkeHUh?=
EB-3 MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwMkm5O|kh|ryP NVrGRm9qW0GQR1XS
MHH-NB-11 Mnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljhTWM2OD1yLkOwOFAzKM7:TR?= NWGzVVg5W0GQR1XS
SK-N-FI NFz5[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2i4[mlEPTB;MD6zNVY6OiEQvF2= MVHTRW5ITVJ?
HCC2157 NIPxNmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLUVJRKSzVyPUCuN|M6OTNizszN NVewVGg6W0GQR1XS
SIMA MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwM{S1PFEh|ryP MX7TRW5ITVJ?
MDA-MB-134-VI MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHkTWM2OD1yLkO2PVI5KM7:TR?= MXzTRW5ITVJ?
NCI-H1694 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\PWmdKSzVyPUCuN|ch|ryP MVfTRW5ITVJ?
EHEB MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITWNJhKSzVyPUCuN|kxQDVizszN NY[2O5RIW0GQR1XS
U-266 M1fLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLsTWM2OD1yLkO5PFQ3KM7:TR?= NGPScmZUSU6JRWK=
LC-1F NVjidmRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXz2eVJZUUN3ME2wMlQ{PzZ3IN88US=> Mn[4V2FPT0WU
SHP-77 MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwNEe4OVUh|ryP M1SwV3NCVkeHUh?=
LS-513 M2nOOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHlRZlbUUN3ME2wMlQ6OzB5IN88US=> NWm3eIp6W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • Concentrations: 0.1-100 pM
  • Incubation Time: 72 hours
  • Method:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • Dosages: 20 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+5% Tween 80+ddH2O
For best results, use promptly after mixing.
2.5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 853.91
Formula

C47H51NO14

CAS No. 33069-62-4
Storage powder
in solvent
Synonyms NSC 125973

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic December 1 2019 Phase 1|Phase 2
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic December 1 2019 Phase 1|Phase 2
NCT03818997 Not yet recruiting Esophageal Cancer|Biliary Tract Cancer|GastroEsophageal Cancer|Hepatobiliary Neoplasm European Organisation for Research and Treatment of Cancer - EORTC|Hoffmann-La Roche|Leap Therapeutics Inc. August 2019 Phase 2
NCT03818997 Not yet recruiting Esophageal Cancer|Biliary Tract Cancer|GastroEsophageal Cancer|Hepatobiliary Neoplasm European Organisation for Research and Treatment of Cancer - EORTC|Hoffmann-La Roche|Leap Therapeutics Inc. August 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • Answer:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • Question 2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • Answer:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products0

Tags: buy Paclitaxel | Paclitaxel supplier | purchase Paclitaxel | Paclitaxel cost | Paclitaxel manufacturer | order Paclitaxel | Paclitaxel distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID